Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for chronic cold agglutinin disease
2009-016966-97Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in cold agglutinin disease (CAD) and Autoimmune hemolytic anemia (AIHA), sponsored by Universitätsmedizin Essen. Primary endpoint: Change in lactate dehydrogenase. Started Feb 2010; status: completed.
02
Drugs
eculizumab
03
Conditions
cold agglutinin disease (CAD)Autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on 2009-016966-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016966-97.